Hsp90 Inhibitor-Evodiamine Conjugates for Colon Cancer Therapy

1.1 MB of data on rationally designed heat shock protein 90 (Hsp90) inhibitor-evodiamine conjugates as antitumor agents. The dataset includes results for conjugate 5a, which demonstrated in vitro antiproliferative activity (IC50 = 7.7 nM) and in vivo tumor growth inhibition of 72.9% via intraperitoneal injection. Yuhang Sun uploaded this dataset to figshare in May 2026.

Use Cases

• Evaluate antitumor efficacy based on in vitro IC50 values mentioned in the description
• Assess oral bioavailability based on in vivo tumor growth inhibition (TGI) results
• Study structure-activity relationships for Hsp90 inhibitor-natural product conjugates

Strengths

• Includes specific potency metrics for a lead compound (IC50 = 7.7 nM for antiproliferation)
• Reports in vivo efficacy results for two administration routes (intraperitoneal and oral)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare

Collection Method

Likely contains experimental results from rational drug design and synthesis.

Freshness

Last updated 2026-05-28 19:45:26; freshness should be verified